+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Myocardial Infarction - Pipeline Insight, 2021

  • ID: 4989210
  • Clinical Trials
  • May 2021
  • Region: Global
  • DelveInsight

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • BioCardia
  • Cynata Therapeutics
  • HUYA Bioscience
  • MedImmune
  • Polyphor Ltd.
This “Myocardial infarction - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Myocardial infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Myocardial infarction Understanding


Myocardial infarction: Overview


Myocardial infarction (MI) is a term used for an event of heart attack which is due to formation of plaques in the interior walls of the arteries resulting in reduced blood flow to the heart and injuring heart muscles because of lack of oxygen supply. The symptoms of MI include chest pain, which travels from left arm to neck, shortness of breath, sweating, nausea, vomiting, abnormal heart beating, anxiety, fatigue, weakness, stress, depression, and other factors. The immediate treatment of MI include, taking aspirin, which prevents blood from clotting, and nitro-glycerin to treat chest pain and oxygen. The heart attack can be prevented by taking an earlier action to lower those risks by controlling diet, fat, cholesterol, salt, smoking, nicotine, alcohol, drugs, monitoring of blood pressure every week, doing exercise every day, and loosing body weight. The treatment of MI includes, aspirin tablets, and to dissolve arterial blockage injection of thrombolytic or clot dissolving drugs such as tissue plasminogen activator, streptokinase or urokinase in blood within 3 h of the onset of a heart attack.

"Myocardial infarction - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myocardial infarction pipeline landscape is provided which includes the disease overview and Myocardial infarction treatment guidelines. The assessment part of the report embraces, in depth Myocardial infarction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myocardial infarction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Myocardial infarction R&D. The therapies under development are focused on novel approaches to treat/improve Myocardial infarction.

Myocardial infarction Emerging Drugs Chapters


This segment of the Myocardial infarction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myocardial infarction Emerging Drugs


Dapagliflozin: AstraZeneca

Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut. The drug is in phase 3 of clinical trials for the treatment of Myocardial infarction.

Remestemcel-L: Mesoblast

AAV-AQP1 is an Adeno-associated virus vector containing gene therapy that contains the human aquaporin-1 gene (AAV2hAQP1) for the treatment of Myocardial infarction. It works on Aquaporin 1 replacement mechanism. It is currently under Phase I/II stage of development. Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. Remestemcel-L is thought to have immunomodulatory properties to counteract the cytokine storms that are implicated in various inflammatory conditions by downregulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues. The drug is in phase 2 of clinical trials for the treatment of Myocardial infarction.

Myocardial infarction: Therapeutic Assessment


This segment of the report provides insights about the different Myocardial infarction drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Myocardial infarction


There are approx. 50+ key companies which are developing the therapies for Myocardial infarction. The companies which have their Myocardial infarction drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Phases


This report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Myocardial infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myocardial infarction: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myocardial infarction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myocardial infarction drugs.

Myocardial infarction Report Insights

  • Myocardial infarction Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Myocardial infarction Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Myocardial infarction drugs?
  • How many Myocardial infarction drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myocardial infarction?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myocardial infarction therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Myocardial infarction and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • AstraZeneca
  • Mesoblast
  • Boehringer Ingelheim
  • PT. Prodia Stem Cell Indonesia
  • Honya Medical Inc
  • Ever Supreme Bio Technology
  • Bayer
  • Athera Biotechnologies
  • MedImmune
  • Polyphor Ltd.
  • Idorsia Pharmaceuticals
  • R-Pharm
  • Faraday Pharmaceuticals
  • CSL Behring
  • Recardio, Inc.
  • Helixmith
  • Quantum Genomics
  • CeleCor Therapeutics
  • Novartis
  • Shanghai Life Science & Technology
  • Dexa Medica Group
  • CellProthera
  • LG Life Sciences
  • Synokem Pharmaceuticals
  • Windtree Therapeutics
  • Quark Pharmaceuticals
  • Kancera
  • BioCardia
  • Actelion Pharmaceuticals
  • Capricor
  • Athersys
  • Bharat Biotech
  • Cynata Therapeutics
  • Hemostemix
  • HUYA Bioscience
  • Inotrem
  • Lee's Pharmaceutical
  • MimeTech
  • NuvOx Pharma
  • OMEICOS Therapeutics
  • Quark Pharmaceuticals
  • Rubicon Biotechnology
  • Silver Creek Pharmaceuticals

Key Products

  • Dapagliflozin
  • Remestemcel-L
  • Empagliflozin
  • Allogeneic umbilical cord mesenchymal stem cells
  • Fulacimstat
  • ATH3G10
  • MEDI6012
  • BAY2433334
  • POL6326
  • ACT-246475
  • RPH-104
  • FDY-5301
  • CSL_112
  • Dutogliptin Tartrate
  • VM202RY
  • Firibastat
  • RUC-4
  • LCZ696
  • DLBS1033
  • LC28-0126
  • Ticagrelor SR
  • MEDI6570
  • Istaroxime
  • QP CP1
  • KAND 567
  • CardiALLO cell therapy
  • Selatogrel
  • CAP 1002
  • Invimestrocel
  • THR-100
  • CYP 001
  • ACP-01
  • HBI-3802
  • Nangibotide
  • Anfibatide
  • MT8
  • OMT 28
  • Fv-Hsp72
  • SGF-1


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Actelion Pharmaceuticals
  • BioCardia
  • Cynata Therapeutics
  • HUYA Bioscience
  • MedImmune
  • Polyphor Ltd.
Introduction

Executive Summary

Myocardial infarction: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Myocardial infarction - Analytical Perspective

In-depth Commercial Assessment
  • Myocardial infarction companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Myocardial infarction Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Dapagliflozin: AstraZeneca
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Remestemcel-L: Mesoblast
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Myocardial infarction Key Companies

Myocardial infarction Key Products

Myocardial infarction- Unmet Needs

Myocardial infarction- Market Drivers and Barriers

Myocardial infarction- Future Perspectives and Conclusion

Myocardial infarction Analyst Views

Myocardial infarction Key Companies

Appendix

List of Tables
Table 1 Total Products for Myocardial infarction
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Myocardial infarction
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Actelion Pharmaceuticals
  • AstraZeneca
  • Athera Biotechnologies
  • Athersys
  • Bayer
  • Bharat Biotech
  • BioCardia
  • Boehringer Ingelheim
  • Capricor
  • CeleCor Therapeutics
  • CellProthera
  • CSL Behring
  • Cynata Therapeutics
  • Dexa Medica Group
  • Ever Supreme Bio Technology
  • Faraday Pharmaceuticals
  • Helixmith
  • Hemostemix
  • Honya Medical Inc
  • HUYA Bioscience
  • Idorsia Pharmaceuticals
  • Inotrem
  • Kancera
  • Lee's Pharmaceutical
  • LG Life Sciences
  • MedImmune
  • Mesoblast
  • MimeTech
  • Novartis
  • NuvOx Pharma
  • OMEICOS Therapeutics
  • Polyphor Ltd.
  • PT. Prodia Stem Cell Indonesia
  • Quantum Genomics
  • Quark Pharmaceuticals
  • R-Pharm
  • Recardio, Inc.
  • Rubicon Biotechnology
  • Shanghai Life Science & Technology
  • Silver Creek Pharmaceuticals
  • Synokem Pharmaceuticals
  • Windtree Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll